As a provider, how should I manage a patient with a PHQ‑9 score of 19 (moderately severe depression)?

Management of PHQ-9 Score of 19 (Moderately Severe Depression)

A PHQ-9 score of 19 requires immediate referral to psychiatry and/or psychology for formal diagnostic evaluation and high-intensity treatment, combined with initiation or optimization of pharmacotherapy in primary care while awaiting specialty consultation. 1, 2

Immediate Safety Assessment (First Priority)

• Evaluate PHQ-9 item 9 (suicidal ideation) immediately, regardless of the total score, as this is the most critical predictor of imminent suicide risk. 1, 2
• Any endorsement of self-harm thoughts (score ≥1 on item 9) mandates same-day emergency psychiatric evaluation, one-to-one observation, and removal of access to lethal means, even though item 9 has low specificity (≈66%) and modest positive predictive value (≈29%). 1, 2
• If item 9 is positive, do not proceed with outpatient management—arrange emergency psychiatric evaluation before any other intervention. 1, 2

Severity Classification and Referral Threshold

• A PHQ-9 score of 19 falls in the moderately severe depression range (15–19), indicating the majority of depressive symptoms are present with moderate-to-marked functional impairment. 2, 3
• This severity level mandates immediate referral to psychiatry and/or psychology—not a "watch-and-wait" approach—because high-intensity interventions from licensed mental health professionals are required. 1, 2
• Proactively arrange the psychiatric referral yourself rather than leaving the task entirely to the patient, as severe depression diminishes motivation and executive function. 1

Screen for Modifiable Risk Factors Before Labeling Treatment-Resistant

• Screen for obstructive sleep apnea using clinical history (snoring, witnessed apneas, daytime somnolence, obesity, hypertension) because untreated sleep disorders significantly diminish antidepressant response. 1
• If sleep apnea is suspected, order a sleep study; if confirmed, initiate CPAP therapy and reassess PHQ-9 after 4–6 weeks of adherent CPAP before making medication changes. 1
• If the sleep study is negative, proceed promptly with medication optimization without further delay. 1

Pharmacotherapy Initiation or Optimization

If the Patient Is Not Currently on an Antidepressant:

• Initiate an SSRI (escitalopram 10 mg daily or sertraline 50 mg daily) as first-line treatment, selecting based on side-effect profile, drug interactions, prior response, age, and patient preference. 3, 4, 5
• Monitor for suicidal thoughts or actions closely, especially in the first few months of treatment or when the dose is changed, as antidepressants may increase suicidal ideation in some patients. 4, 5
• Schedule follow-up within 1–2 weeks after initiation to assess tolerability, adherence, and early response. 1

If the Patient Is Already on an SSRI at Standard Dose:

• Increase escitalopram to 30 mg daily if currently on 20 mg, as higher doses demonstrate dose-dependent efficacy in treatment-resistant depression. 1
• Reassess PHQ-9 at 2–4 weeks after dose escalation, then continue monthly monitoring. 1
• If dose escalation is insufficient after 4–6 weeks, switch to venlafaxine extended-release (start 75 mg daily, titrate to 150–225 mg) for dual serotonin-norepinephrine reuptake inhibition. 1

If the Patient Has Partial Response to an SSRI:

• Add bupropion 150–300 mg daily to address residual anhedonia and fatigue in patients with only partial improvement. 1

Required Treatment Components

• Combination of pharmacotherapy and psychotherapy is mandatory for moderately severe depression; psychotherapy alone is insufficient at this severity level. 1
• High-intensity individual evidence-based therapy (cognitive behavioral therapy, behavioral activation, biobehavioral strategies, education, relapse prevention) should be delivered by licensed mental health professionals. 3
• If the patient has a regular partner and relationship issues contribute to depression, consider behavioral couples therapy. 2, 3

Monitoring and Response Criteria

• Repeat PHQ-9 within 1–2 weeks after any medication change, then at 4,8, and 12 weeks to monitor trajectory. 1
• Treatment response is defined as either a ≥50% reduction in PHQ-9 score or achieving a score <10. 1
• If PHQ-9 remains ≥15 after 8–12 weeks of optimized therapy, an immediate psychiatric referral is mandated (if not already completed). 1

Additional Risk Factors Requiring Urgent Specialty Referral

Even if the patient has a PHQ-9 of 19, expedite psychiatric referral if any of the following are present: 3

• Prior mood disorder (treated or untreated)
• Comorbid anxiety disorder or substance-use disorder
• Advanced or progressive medical disease
• Social isolation (single, widowed, divorced)
• Unemployment with limited financial resources
• Low educational attainment (<high school)

Critical Pitfalls to Avoid

• Do not manage PHQ-9 ≥15 in primary care alone without specialist involvement; this constitutes undertreatment of severe depression. 1, 2
• Do not accept a single reversible explanation (such as sleep apnea) for moderately severe depression without treating the depression itself—this cognitive error delays essential care. 1
• Do not defer to patient preference for delaying treatment when PHQ-9 ≥15 and depressive symptoms markedly impair functioning; clinical judgment should supersede patient preference in this context. 1
• Do not omit assessment of item 9 at every follow-up visit, as suicide risk can appear rapidly even when previously denied. 1, 2

Antidepressant Safety Monitoring

• Watch for serotonin syndrome (agitation, hallucinations, coordination problems, muscle twitching, racing heartbeat, fever, nausea, muscle rigidity) and seek emergency care if suspected. 4, 5
• Monitor for abnormal bleeding risk, especially if the patient takes warfarin, NSAIDs, or aspirin. 4, 5
• Assess for hyponatremia (headache, weakness, confusion, memory problems), particularly in elderly patients. 4, 5
• Screen for manic episodes (greatly increased energy, severe insomnia, racing thoughts, reckless behavior, excessive happiness or irritability). 4, 5
• Do not stop antidepressants abruptly; taper gradually to avoid discontinuation syndrome (anxiety, irritability, mood changes, headache, sweating, nausea, dizziness, electric shock-like sensations). 4, 5